| VIS ID | Virus | Ensembl ID | Gene Type | Target Gene | Oncogene | Tumor Suppressor Gene | NCBI ID | Uniprot ID |
|---|---|---|---|---|---|---|---|---|
| TVIS20034276 | HPV | ENSG00000179546.5 | protein_coding | HTR1D | No | No | 3352 | P28221 |
| TVIS20034277 | HPV | ENSG00000179546.5 | protein_coding | HTR1D | No | No | 3352 | P28221 |
| TVIS20034280 | HPV | ENSG00000179546.5 | protein_coding | HTR1D | No | No | 3352 | P28221 |
| TVIS20047208 | HPV | ENSG00000179546.5 | protein_coding | HTR1D | No | No | 3352 | P28221 |
| TVIS20034278 | HPV | ENSG00000179546.5 | protein_coding | HTR1D | No | No | 3352 | P28221 |
| TVIS20034282 | HPV | ENSG00000179546.5 | protein_coding | HTR1D | No | No | 3352 | P28221 |
| TVIS20034283 | HPV | ENSG00000179546.5 | protein_coding | HTR1D | No | No | 3352 | P28221 |
| TVIS20047211 | HPV | ENSG00000179546.5 | protein_coding | HTR1D | No | No | 3352 | P28221 |
| TVIS20047209 | HPV | ENSG00000179546.5 | protein_coding | HTR1D | No | No | 3352 | P28221 |
| TVIS20034281 | HPV | ENSG00000179546.5 | protein_coding | HTR1D | No | No | 3352 | P28221 |
Target Gene Table
▼
TCGA Plot Options
▼
Drug Information
▼
| Gene | HTR1D |
|---|---|
| DrugBank ID | DB00953 |
| Drug Name | Rizatriptan |
| Target ID | BE0000659 |
| UniProt ID | P28221 |
| Regulation Type | agonist |
| PubMed IDs | 11752352; 9127118; 8904614; 9056052; 11487512; 15821444; 12093318; 12269863; 15056946 |
| Citations | Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5.@@Longmore J, Hargreaves RJ, Boulanger CM, Brown MJ, Desta B, Ferro A, Schofield WN, Taylor AA, Hill RG: Comparison of the vasoconstrictor properties of the 5-HT1D-receptor agonists rizatriptan (MK-462) and sumatriptan in human isolated coronary artery: outcome of two independent studies using different experimental protocols. Funct Neurol. 1997 Jan-Feb;12(1):3-9.@@Longmore J, Boulanger CM, Desta B, Hill RG, Schofield WN, Taylor AA: 5-HT1D receptor agonists and human coronary artery reactivity in vitro: crossover comparisons of 5-HT and sumatriptan with rizatriptan and L-741,519. Br J Clin Pharmacol. 1996 Oct;42(4):431-41.@@Sciberras DG, Polvino WJ, Gertz BJ, Cheng H, Stepanavage M, Wittreich J, Olah T, Edwards M, Mant T: Initial human experience with MK-462 (rizatriptan): a novel 5-HT1D agonist. Br J Clin Pharmacol. 1997 Jan;43(1):49-54.@@Williamson DJ, Hill RG, Shepheard SL, Hargreaves RJ: The anti-migraine 5-HT(1B/1D) agonist rizatriptan inhibits neurogenic dural vasodilation in anaesthetized guinea-pigs. Br J Pharmacol. 2001 Aug;133(7):1029-34.@@Wackenfors A, Jarvius M, Ingemansson R, Edvinsson L, Malmsjo M: Triptans induce vasoconstriction of human arteries and veins from the thoracic wall. J Cardiovasc Pharmacol. 2005 May;45(5):476-84.@@Wellington K, Plosker GL: Rizatriptan: an update of its use in the management of migraine. Drugs. 2002;62(10):1539-74.@@Wellington K, Jarvis B: Spotlight on rizatriptan in migraine. CNS Drugs. 2002;16(10):715-20.@@Ikemoto F, Toru T, Aijima H, Natsumeda Y: [Rizatriptan (Maxalt), a new entity of triptan for migraine: pharmacology and therapeutic relevance]. Nihon Yakurigaku Zasshi. 2004 Apr;123(4):295-302. |
| Groups | Approved |
| Direct Classification | Tryptamines and derivatives |
| SMILES | CN(C)CCC1=CNC2=C1C=C(CN1C=NC=N1)C=C2 |
| Pathways | |
| PharmGKB | PA451264 |
| ChEMBL | CHEMBL905 |
